Tier 3 — preclinical

Neuropsychiatric Effects of Creatine: What Does the Preclinical and Clinical Evidence Conclude?

Maximiliano Abarca, Alejandra González, Isabel Dosal, Isadora León, Marcelo Arancibia
Rev Med Chil 2026 154(3):430-439

Bibliography

PubMed
PMID 42257668
DOI
10.4067/s0034-98872026000300430
Funding
No explicit funding statement was located in the accessible PubMed or publisher records during Biohack Blueprint's 2026-10-02 audit. This is an audit-status statement, not confirmation that the study received no funding.
Competing interests
No explicit competing-interests statement was located in the accessible PubMed or publisher records during Biohack Blueprint's 2026-10-02 audit. This is an audit-status statement, not confirmation that no competing interests existed.

Study snapshot

DesignNarrative review
ModelPreclinical and human evidence
SampleNarrative synthesis
InterventionCreatine supplementation across neuropsychiatric and cognitive research
DurationVaried
EndpointsMood disorders; Cognition; Brain bioenergetics; Neuroinflammation; Synaptic plasticity

What the study showed, in plain terms

Spanish-language review summarizing proposed neuropsychiatric effects of creatine across animal and human evidence.

Key findings

The review describes positive signals in affective disorders and selected cognitive domains while emphasizing that protocols and population-specific effects require further study and that bipolar-disorder evidence is uncertain.

What this study can and cannot tell us

Narrative review combining heterogeneous preclinical, observational and interventional evidence; conclusions are not equivalent to a creatine-specific systematic meta-analysis.

Citation network

Articles citing this research paper

1 article

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction